Welcome to our dedicated page for Ipsen Sa news (Ticker: IPSEY), a resource for investors and traders seeking the latest updates and insights on Ipsen Sa stock.
Ipsen SA (ADR: IPSEY) generates a steady flow of news centered on its activities as a global, mid-sized biopharmaceutical company focused on Oncology, Rare Disease and Neuroscience. This news page aggregates company announcements, partner releases and regulatory updates that mention Ipsen and its ADR program, giving readers a focused view of developments that can influence perceptions of IPSEY.
Recent news highlights Ipsen’s role in advancing specialty care medicines. In oncology, the company has reported Phase III NAPOLI 3 trial results for an investigational Onivyde-based regimen (NALIRIFOX) in previously untreated metastatic pancreatic ductal adenocarcinoma, with statistically significant improvements in overall and progression-free survival compared to a nab-paclitaxel plus gemcitabine regimen. Ipsen has also nominated a first clinical drug candidate from its multi-year oncology collaboration with Marengo Therapeutics, based on Marengo’s STAR T cell activator platform for solid tumors.
In rare diseases, news items cover Ipsen’s work in pediatric cholestatic liver diseases and ultra-rare conditions. Examples include Health Canada’s approval of Bylvay (odevixibat) for pruritus due to Progressive Familial Intrahepatic Cholestasis, under a partnership with Medison Pharma, and regulatory interactions for palovarotene in fibrodysplasia ossificans progressiva, including a CHMP negative opinion and a U.S. FDA Complete Response Letter. Corporate news also details Ipsen’s agreement to acquire Albireo, adding Bylvay and other bile acid modulators to its rare disease portfolio.
Neuroscience and rare neurological disease updates feature Ipsen’s collaboration with Skyhawk Therapeutics to discover RNA-targeting small molecules for rare neurological diseases. Partner announcements describe Ipsen’s option to obtain exclusive global rights to development candidates and its responsibility for later-stage development and commercialization.
Investors and observers can use this news feed to follow Ipsen’s clinical trial readouts, regulatory decisions, licensing deals, acquisitions and capital markets disclosures that reference IPSEY. Regularly reviewing these updates can help contextualize the company’s therapeutic focus and strategic direction as reflected in public announcements.
Ipsen has successfully completed the acquisition of Epizyme, Inc., purchasing all outstanding shares for $1.45 per share plus a contingent value right of $1.00 per share. Following this transaction, Epizyme will operate as an Ipsen company. The acquisition includes Epizyme's lead product, Tazverik (tazemetostat), an EZH2 inhibitor, already approved for certain types of lymphoma and sarcoma. Ipsen also gains development candidate EZM0414, a SETD2 inhibitor under Phase I/Ib trials. This strategic move is expected to enhance Ipsen's oncology portfolio and patient reach.
Ipsen has reported its total share capital and voting rights as of 31 July 2022. The total number of shares is 83,814,526. The gross total of voting rights stands at 132,118,807, while the net total is 130,970,618. This report follows regulatory requirements under French law, specifically Article L.233-8 II and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers.
On February 8, 2022, Ipsen reported a transaction involving the purchase of 8,000 shares at a daily weighted average price of €95.4471 on the XPAR platform. The issuer identification code is 549300M6SGDPB4Z94P11, with the financial instrument's identification code being FR0010259150. This acquisition reflects Ipsen's active engagement in market activities, underscoring the company's commitment to managing its share capital effectively.
Ipsen S.A. has extended the expiration date for its tender offer to acquire Epizyme, Inc. shares to August 11, 2022. The offer values Epizyme shares at $1.45 each, plus a contingent value right potentially worth up to $1.00. This extension allows additional time for compliance with the Hart-Scott-Rodino Antitrust Improvements Act. As of August 4, 2022, approximately 42.3 million shares—around 25% of Epizyme's outstanding shares—have been tendered. Stockholders are encouraged to accept the offer, and previously tendered shares do not need to be re-submitted.
Ipsen announced that its Phase III RESILIENT trial for Onivyde (irinotecan liposomal injection) in small cell lung cancer did not meet the primary endpoint of overall survival compared to topotecan. Although the trial did show a doubling of the objective response rate in favor of Onivyde, it raises concerns for investors regarding efficacy. The safety profile remained consistent with previous studies, causing no new safety issues. Detailed results will be shared at a medical conference, and data will be communicated to regulatory agencies.
On July 26, 2022, Ipsen reported aggregate trading details, highlighting a total volume of 9,218 shares across two transaction days. The daily weighted average price of shares was 91.0254 on July 25, and 89.2192 on July 26. The data indicates notable trading activity on the XPAR platform, revealing key metrics that investors should analyze. The information is crucial for assessing market movements and potential investment decisions for IPSEY.
Ipsen has partnered with Marengo Therapeutics to develop two preclinical oncology candidates using Marengo's TCR Vβ-targeted T cell activation approach. Ipsen will pay $45 million upfront and may pay up to $1.592 billion in milestone payments, plus royalties. Marengo will lead preclinical development, with Ipsen handling clinical development and commercialization. This collaboration aims to enhance Ipsen's oncology pipeline, with both companies bringing substantial expertise to the partnership.
Ipsen (Euronext: IPN; ADR: IPSEY) reported strong H1 2022 financial results with a total sales increase of 15.2% to €1.43 billion, driven by robust growth in oncology and neuroscience segments. Core consolidated net profit rose by 19.9% to €420 million, while IFRS net profit jumped 30% to €394 million. The core operating margin improved to 39.6%. Ipsen announced an agreement to acquire Epizyme to enhance its oncology portfolio and completed the divestiture of its Consumer HealthCare business. Full-year guidance was upgraded to reflect anticipated sales growth of over 7% at constant currency.
IPSEN reported an aggregated presentation of financial transactions for its shares on the XPAR platform for the week of July 18-22, 2022. Total transactions included 8,911 shares with a daily weighted average price of €92.4400. Key transaction dates were July 18, 20, 21, and 22, with notable volumes including 4,500 shares on July 18 and 2,300 shares on July 22. This release provides insight into the trading activity of IPSEN, which is essential for investors tracking market performance.
The press release from Ipsen details a recent stock transaction involving 2,027 shares at a weighted average price of 91.9164 on July 15, 2022. The issuer identification code provided is 549300M6SGDPB4Z94P11, with the financial instrument code being FR0010259150. The transaction occurred on the XPAR platform.
FAQ
What is the current stock price of Ipsen Sa (IPSEY)?
What is the market cap of Ipsen Sa (IPSEY)?
